论文部分内容阅读
目的:探讨免疫组化在肝癌诊断中的作用。方法:遴选我院178例肝癌患者,其中PHC组90例,继发性肝癌组88例和90例健康人作为对照。测定每组AFP、AFU、SF和CA19-9的检测水平以及各项标志物联检的水平。结果:PHC组各项值明显呈阳性,正常对照组均呈阴性,继发性肝癌组居中。PHC组AFP的阳性检出率为78.89%,AFU的阳性检出率为65.56%,SF的阳性检出率为53.33%,CA19-9的阳性检出率为58.89%,各项联检的阳性检出率为95.56%。结论:AFP、AFU、SF和CA19-9联合检测能大大提高肝癌的检出率,有助于PHC的早期诊断和治疗。
Objective: To investigate the role of immunohistochemistry in the diagnosis of liver cancer. Methods: A total of 178 HCC patients were selected, including 90 PHC patients, 88 HCC patients and 90 healthy controls. The levels of AFP, AFU, SF and CA19-9 in each group and the level of each marker were detected. Results: All the values of PHC group were obviously positive, while those in the normal control group were all negative. The positive detection rate of AFP in PHC group was 78.89%, the positive detection rate of AFU was 65.56%, the positive detection rate of SF was 53.33%, the positive detection rate of CA19-9 was 58.89% Rate of 95.56%. Conclusion: The combined detection of AFP, AFU, SF and CA19-9 can greatly improve the detection rate of liver cancer and contribute to the early diagnosis and treatment of PHC.